QIAGEN N.V.
QGEN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for QGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QGEN
QIAGEN N.V. is a global provider of sample and assay technologies for molecular diagnostics, applied testing, and life sciences research, with a focus on delivering integrated solutions to customers worldwide.
Key risk: Intense competition
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$8.90B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials for QIAGEN N.V..
QIAGEN N.V. is a global provider of sample and assay technologies for molecular diagnostics, applied testing, and life sciences research, with a focus on delivering integrated solutions to customers worldwide.
- QIAGEN reported total revenue of $2,090.0M and net income of $424.9M for the fiscal year ended December 31, 2025 [sec].
- As of December 31, 2025, the company held cash & equivalents of $839.0M and had total debt of $1,654.4M [sec].
- The company generated net cash from operating activities of $654.3M in 2025, compared to $673.6M in 2024 [sec · filed 2026-03-20].
- QIAGEN faces intense competition from companies with greater financial and R&D resources, and its growth depends on converting users from competing products [sec · filed 2025-03-31].
- The company relies on collaborative commercial relationships to develop and market some products, and disruptions in these partnerships could affect business [sec · filed 2026-03-20].
What works
- QIAGEN has a strong cash position of $839.0M as of December 31, 2025, providing liquidity for operations and strategic initiatives [sec].
- The company achieved a net income of $424.9M in 2025, reflecting solid profitability [sec].
- Operating income improved significantly to $465.9M in 2025 from $97.7M in 2024, indicating enhanced operational efficiency [sec · filed 2026-03-20].
- QIAGEN expects to meet short-term capital needs through cash flow from operations and cash on hand, reducing reliance on external financing [sec · filed 2026-03-20].
What to weigh
- QIAGEN operates in highly competitive markets where many competitors have greater financial, operational, and R&D resources [sec · filed 2025-03-31].
- The company faces risks from potential reductions in government funding for life sciences research, which could significantly impact its business [sec · filed 2026-03-20].
- Failure to effectively manage growth or integrate acquisitions could lead to operational inefficiencies, delays, and increased expenses [sec · filed 2026-03-20].
- The company relies on external partners for product development and marketing, and any disruption in these relationships could affect development timelines and commercial performance [sec · filed 2026-03-20].
From the filings
Quoted directly from source documents.
QIAGEN's net income for 2025 was $424.9 million.
“net income was $424.9 million in 2025”
SEC filings · March 20, 2026
QIAGEN expects to meet short-term capital needs through cash flow from operations and cash on hand.
“We expect to meet short-term capital needs through cash flow from operations and cash on hand.”
SEC filings · March 20, 2026
The company faces competition from entities with greater resources.
“Many competitors have greater financial, operational, sales, marketing and research and development resources.”
SEC filings · March 20, 2026
QIAGEN relies on collaborative commercial relationships for some products.
“We rely on collaborative commercial relationships to develop and/or market some of our products.”
SEC filings · March 20, 2026
Risks & what to watch (4)›
Key risks
- Intense competition — Many competitors have greater financial and R&D resources; new technologies could render QIAGEN's products obsolete [sec · filed 2025-03-31].
- Government funding cuts — Reductions in NIH and other global research agency budgets could significantly impact business [sec · filed 2026-03-20].
- Growth management challenges — Failure to manage growth or integrate acquisitions could cause operational inefficiencies and increased costs [sec · filed 2026-03-20].
- Partner dependency — Disruption in collaborative relationships could delay development and affect commercial performance [sec · filed 2026-03-20].
What to watch
- Monitor QIAGEN's ability to maintain or improve operating margins given competitive pressures and fixed cost burdens [sec · filed 2025-03-31].
- Watch for any changes in government funding for life sciences research that could affect demand for QIAGEN's products [sec · filed 2026-03-20].
- Track the company's success in integrating acquisitions and scaling operations without disruption [sec · filed 2026-03-20].
- Observe the performance of collaborative partnerships and their impact on product development and market access [sec · filed 2026-03-20].
Sources: SEC filings · Generated August 26, 2026 · How we verify sources →
Run QIAGEN N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available QIAGEN N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.66 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
343
Total value held
$4.78B
| Holder | Shares | Value |
|---|---|---|
| wellington management group llp | 14,364,303 | $575.1M |
| vanguard capital management llc | 12,212,550 | $494.7M |
| deutsche bank ag\ | 5,601,957 | $224.3M |
| blackrock, inc. | 5,250,461 | $210.2M |
| morgan stanley | 4,190,913 | $167.8M |
| earnest partners llc | 3,868,489 | $154.9M |
| bank of america corp /de/ | 3,246,973 | $130.0M |
| fivespan partners, lp | 2,689,243 | $107.7M |
| allspring global investments holdings, llc | 2,481,645 | $100.2M |
| capital international investors | 2,436,169 | $97.5M |
Showing top 10 of 343 institutional holders of QIAGEN N.V.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.5%
- Days to cover
- 3.3
- Shares short
- 6,353,079
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for QIAGEN N.V.?
QIAGEN N.V. is a global provider of sample and assay technologies for molecular diagnostics, applied testing, and life sciences research, with a focus on delivering integrated solutions to customers worldwide.
Who is the CEO of QIAGEN N.V.?
Mr. Thierry L. Bernard is the chief executive officer of QIAGEN N.V. (QGEN).
Where is QIAGEN N.V. headquartered?
QIAGEN N.V. (QGEN) is headquartered in Venlo, Netherlands.
What therapeutic areas does QIAGEN N.V. focus on?
QIAGEN N.V. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.